Capital One National Association lessened its position in shares of Abbott Laboratories (NYSE:ABT) by 12.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,855 shares of the healthcare product maker’s stock after selling 3,774 shares during the quarter. Capital One National Association’s holdings in Abbott Laboratories were worth $1,532,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in ABT. Rowland & Co. Investment Counsel ADV acquired a new position in shares of Abbott Laboratories during the 4th quarter valued at about $102,000. Heritage Trust Co grew its holdings in shares of Abbott Laboratories by 10.1% during the 2nd quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock worth $106,000 after purchasing an additional 200 shares during the period. Tributary Capital Management LLC purchased a new stake in shares of Abbott Laboratories during the 3rd quarter worth about $106,000. Thompson Davis & CO. Inc. grew its holdings in shares of Abbott Laboratories by 17.7% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock worth $120,000 after purchasing an additional 370 shares during the period. Finally, Cerebellum GP LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth about $133,000. 72.37% of the stock is owned by institutional investors and hedge funds.
ABT traded up $0.38 during trading on Thursday, hitting $58.83. The company’s stock had a trading volume of 4,572,315 shares, compared to its average volume of 7,050,387. The company has a market cap of $103,278.19, a price-to-earnings ratio of 23.53, a PEG ratio of 1.75 and a beta of 1.50. Abbott Laboratories has a 12 month low of $42.31 and a 12 month high of $64.60. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.86 and a current ratio of 2.26.
Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, January 24th. The healthcare product maker reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The company had revenue of $7.59 billion during the quarter, compared to the consensus estimate of $7.38 billion. Abbott Laboratories had a return on equity of 13.88% and a net margin of 1.74%. The firm’s quarterly revenue was up 42.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.65 earnings per share. research analysts predict that Abbott Laboratories will post 2.86 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 13th will be paid a dividend of $0.28 per share. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.90%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 44.80%.
A number of equities analysts have weighed in on ABT shares. Barclays restated a “buy” rating and issued a $66.00 price target on shares of Abbott Laboratories in a report on Monday, January 8th. BTIG Research cut Abbott Laboratories from a “buy” rating to a “neutral” rating in a research note on Monday, January 22nd. They noted that the move was a valuation call. Leerink Swann reaffirmed a “market perform” rating and issued a $68.00 target price (up from $60.00) on shares of Abbott Laboratories in a research report on Thursday, January 25th. Morgan Stanley increased their price target on Abbott Laboratories from $67.00 to $70.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Finally, JPMorgan Chase raised Abbott Laboratories from a “neutral” rating to an “overweight” rating and set a $60.00 target price for the company in a research note on Tuesday, January 2nd. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $65.47.
In other Abbott Laboratories news, SVP Jared Watkin sold 996 shares of the business’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $58.87, for a total value of $58,634.52. Following the completion of the transaction, the senior vice president now directly owns 69,511 shares of the company’s stock, valued at $4,092,112.57. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Roger Bird sold 8,262 shares of the business’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $62.75, for a total value of $518,440.50. Following the completion of the transaction, the insider now directly owns 58,574 shares of the company’s stock, valued at $3,675,518.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 124,261 shares of company stock valued at $7,559,987. 0.74% of the stock is owned by insiders.
WARNING: This report was originally posted by Macon Daily and is the sole property of of Macon Daily. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://macondaily.com/2018/04/12/capital-one-national-association-has-1-53-million-stake-in-abbott-laboratories-abt-updated-updated-updated.html.
About Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.